Delivering the world’s first population scale molecular diagnostics.
Metasight is delivering the world’s first population-scale molecular diagnostics.
Metasight leveraged liquid biopsies for disease diagnosis, monitoring, and prognosis. Their unique approach to identifying disease signatures involves proprietary, multi-omics technology combined with population-scale serum samples and electronic health records. This approach enables robust, high-throughput, and cost-effective screening, all through a single blood test.
SECTOR
Health Sciences
INVESTED
2024
STATUS
Acquired by Guardant Health Inc (NASDAQ: GH)
HQ
Rehovot, Israel
FOUNDERS
Prof. Tomer Shlomi
Subscribe to hear about Arc Ventures' updates and events.
